Overview


According to FutureWise analysis the market for dementia drugs in 2023 is US$ 10.28 billion, and is expected to reach US$ 20.07 billion by 2031 at a CAGR of 8.72%.

Dementia refers to a condition that manifests as a series of related symptoms. These symptoms can negatively impact a person's ability and motivation to perform daily activities. Apart from memory impairment, disruption of thought patterns, and emotional problems, the most common symptoms are decreased motivation. It is possible to describe the symptoms as occurring in a continuum that spans several stages. Consciousness does not suffer from these symptoms. The individual, caregivers, and social relationships will all be affected by dementia. Dementia can be diagnosed by observing a significant change in a person's mental functioning and an increase in the number of caregivers. This is a neurodegenerative condition. The Diagnostic Statistical Manual of Mental Disorders Fifth Edition (DSM-5) has re-described the condition as a major neurological disorder with varying degrees of severity, and many cause subtypes.

The International Classification of Diseases ( ICD-11 ) classifies dementia as a neurocognitive condition with multiple forms and subclasses. An acquired brain syndrome is a condition that causes a decline in cognitive function. It is also listed in contrast to neurodevelopmental conditions. Some subtypes of dementia are based on known conditions such as Parkinson's Disease, Huntington's Disease, or Prion diseases. The subtypes can be based on different symptoms. This could be due to a neurodegenerative condition: frontotemporal Lobar Degeneration for frontotemporal dementia or Lewy Body disease in dementia with Lewy bodies. mixed dementia is a combination of multiple types of dementia. The symptoms and signs of dementia can also be called a neuropsychiatric syndrome. These symptoms include restlessness, agitation, and sexual disinhibition. These symptoms could be caused by impairments in cognitive inhibition. There are many stages of dementia. The progression of symptoms is gradual and can be seen in the early stages. There may be other conditions such as high cholesterol or diabetes. Sometimes, there may even be four. Dementia sufferers are more likely than others to experience incontinence problems: They are three times more likely to have urinary and are four times more likely to have incontinence than people of similar age. Different symptoms can indicate dementia. It can affect memory, attention span, and communication. You may notice signs of dementia such as being lost in your neighborhood, using unfamiliar words to refer to familiar objects or forgetting the name and friend of a family member, forgetting old memories, being unable to do tasks independently, etc.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Dementia Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Dementia Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Apotex Inc
  • Aurobindo Pharma
  • Eisai Co. Ltd
  • Eli Lilly and Company
  • Johnson and Johnson
  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Zydus Cadila
  • Janssen Pharmaceuticals Inc
  • Biogen Pharmaceuticals

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Class

  • MAO Inhibitors
  • Glutamate Inhibitors
  • Cholinesterase Inhibitors

By Indication

  • Lewy Boady Dementia
  • Parkinson's Disease dementia
  • Alzheimer's Disease
  • Vascular Dementia
  • Other indications

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Dementia Drugs Market By Drug Class, By Indication, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Dementia Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Dementia Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Dementia Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Dementia Drugs Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. MAO Inhibitors
        2. Glutamate Inhibitors
        3. Cholinesterase Inhibitors

  • 8.   Dementia Drugs Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Lewy Boady Dementia
        2. Parkinson's Disease dementia
        3. Alzheimer's Disease
        4. Vascular Dementia
        5. Other indications

  • 9.   Dementia Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others

  • 10.   North America Dementia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Dementia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Dementia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Dementia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Dementia Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Apotex Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Aurobindo Pharma
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Eisai Co. Ltd
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Eli Lilly and Company
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Johnson and Johnson
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Pfizer Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Teva Pharmaceuticals
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Zydus Cadila
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Janssen Pharmaceuticals Inc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Biogen Pharmaceuticals
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients